90 related articles for article (PubMed ID: 16870428)
1. Kinase-mediated trapping of bi-functional conjugates of paclitaxel or vinblastine with thymidine in cancer cells.
Aspland SE; Ballatore C; Castillo R; Desharnais J; Eustaquio T; Goelet P; Guo Z; Li Q; Nelson D; Sun C; Castellino AJ; Newman MJ
Bioorg Med Chem Lett; 2006 Oct; 16(19):5194-8. PubMed ID: 16870428
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell targeting of transferrin-PEG-TNF-alpha conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation.
Jiang YY; Liu C; Hong MH; Zhu SJ; Pei YY
Bioconjug Chem; 2007; 18(1):41-9. PubMed ID: 17226956
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
4. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Coley HM; Shotton CF; Ajose-Adeogun A; Modjtahedi H; Thomas H
Biochem Pharmacol; 2006 Oct; 72(8):941-8. PubMed ID: 16934227
[TBL] [Abstract][Full Text] [Related]
5. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide.
Vlahov IR; Santhapuram HK; Kleindl PJ; Howard SJ; Stanford KM; Leamon CP
Bioorg Med Chem Lett; 2006 Oct; 16(19):5093-6. PubMed ID: 16870437
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles for drug delivery in cancer treatment.
Haley B; Frenkel E
Urol Oncol; 2008; 26(1):57-64. PubMed ID: 18190833
[TBL] [Abstract][Full Text] [Related]
7. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
8. Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles.
Seow WY; Xue JM; Yang YY
Biomaterials; 2007 Mar; 28(9):1730-40. PubMed ID: 17182095
[TBL] [Abstract][Full Text] [Related]
9. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps.
Kasibhatla S; Baichwal V; Cai SX; Roth B; Skvortsova I; Skvortsov S; Lukas P; English NM; Sirisoma N; Drewe J; Pervin A; Tseng B; Carlson RO; Pleiman CM
Cancer Res; 2007 Jun; 67(12):5865-71. PubMed ID: 17575155
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors.
Baloglu E; Miller ML; Roller EE; Cavanagh EE; Leece BA; Goldmacher VS; Chari RV
Bioorg Med Chem Lett; 2004 Dec; 14(23):5885-8. PubMed ID: 15501062
[TBL] [Abstract][Full Text] [Related]
11. Synuclein-gamma targeting peptide inhibitor that enhances sensitivity of breast cancer cells to antimicrotubule drugs.
Singh VK; Zhou Y; Marsh JA; Uversky VN; Forman-Kay JD; Liu J; Jia Z
Cancer Res; 2007 Jan; 67(2):626-33. PubMed ID: 17234772
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of molecular cancer therapeutics.
van Montfort RL; Workman P
Trends Biotechnol; 2009 May; 27(5):315-28. PubMed ID: 19339067
[TBL] [Abstract][Full Text] [Related]
13. Microtubule assembly dynamics: an attractive target for anticancer drugs.
Singh P; Rathinasamy K; Mohan R; Panda D
IUBMB Life; 2008 Jun; 60(6):368-75. PubMed ID: 18384115
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel prodrugs: toward smarter delivery of anticancer agents.
Skwarczynski M; Hayashi Y; Kiso Y
J Med Chem; 2006 Dec; 49(25):7253-69. PubMed ID: 17149855
[No Abstract] [Full Text] [Related]
15. Synthesis and antitumor activity of peptide-paclitaxel conjugates.
Papas S; Akoumianaki T; Kalogiros C; Hadjiarapoglou L; Theodoropoulos PA; Tsikaris V
J Pept Sci; 2007 Oct; 13(10):662-71. PubMed ID: 17787026
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, structure--selectivity relationship, and effect on human cancer cells of a novel series of histone deacetylase 6-selective inhibitors.
Itoh Y; Suzuki T; Kouketsu A; Suzuki N; Maeda S; Yoshida M; Nakagawa H; Miyata N
J Med Chem; 2007 Nov; 50(22):5425-38. PubMed ID: 17929798
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells.
Zhou H; Wu S; Zhai S; Liu A; Sun Y; Li R; Zhang Y; Ekins S; Swaan PW; Fang B; Zhang B; Yan B
J Med Chem; 2008 Mar; 51(5):1242-51. PubMed ID: 18257542
[TBL] [Abstract][Full Text] [Related]
18. Nanocarrier-assisted sub-cellular targeting to the site of mitochondria improves the pro-apoptotic activity of paclitaxel.
D'Souza GG; Cheng SM; Boddapati SV; Horobin RW; Weissig V
J Drug Target; 2008 Aug; 16(7):578-85. PubMed ID: 18686127
[TBL] [Abstract][Full Text] [Related]
19. Design and development of water-soluble curcumin conjugates as potential anticancer agents.
Safavy A; Raisch KP; Mantena S; Sanford LL; Sham SW; Krishna NR; Bonner JA
J Med Chem; 2007 Nov; 50(24):6284-8. PubMed ID: 17973470
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and ceramide synergistically induce cell death with transient activation of EGFR and ERK pathway in pancreatic cancer cells.
Qiu L; Zhou C; Sun Y; Di W; Scheffler E; Healey S; Wanebo H; Kouttab N; Chu W; Wan Y
Oncol Rep; 2006 Oct; 16(4):907-13. PubMed ID: 16969513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
